Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.
10.1007/s11684-021-0847-4
- Author:
Rongtao LAI
1
;
Tianhui ZHOU
1
;
Xiaogang XIANG
1
;
Jie LU
1
;
Haiguang XIN
2
;
Qing XIE
3
Author Information
1. Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
2. Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. allanxin@hotmail.com.
3. Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. xieqingrjh@163.com.
- Publication Type:Letter
- Keywords:
COVID-19;
SARS-CoV-2;
antibody cocktail;
neutralizing antibody;
therapeutic strategy
- MeSH:
Antibodies, Monoclonal/therapeutic use*;
Antibodies, Neutralizing;
Antibodies, Viral;
COVID-19;
Humans;
SARS-CoV-2;
Spike Glycoprotein, Coronavirus
- From:
Frontiers of Medicine
2021;15(4):644-648
- CountryChina
- Language:English
-
Abstract:
The coronavirus disease 2019 (COVID-19) has caused global public health and economic crises. Thus, new therapeutic strategies and effective vaccines are urgently needed to cope with this severe pandemic. The development of a broadly neutralizing antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the attractive treatment strategies for COVID-19. Currently, the receptor-binding domain (RBD) of the spike (S) protein is the main target of neutralizing antibodies when SARS-CoV-2 enters human cells through an interaction between the S protein and the angiotensin-converting enzyme 2 expressed on various human cells. A single monoclonal antibody (mAb) treatment is prone to selective pressure due to increased possibility of targeted epitope mutation, leading to viral escape. In addition, the antibody-dependent enhancement effect is a potential risk of enhancing the viral infection. These risks can be reduced using multiple mAbs that target nonoverlapping epitopes. Thus, a cocktail therapy combining two or more antibodies that recognize different regions of the viral surface may be the most effective therapeutic strategy.
